Transcode Therapeutics

RNAZNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$25.396 M

$1.50 -6.25%

Close of 6 Nov 2026

As of 6 Nov 2026, Transcode Therapeutics (RNAZ) has a market capitalization of $25.4M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$34.7M

Loss-making

Shares outstanding

16,930,739

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#369BeyondSpringBYSI$26.6M
#370Abvc BiopharmaABVC$26.3M
#371Transcode TherapeuticsRNAZ$25.4M
#372Aardvark TherapeuticsAARD$24.5M
#373Shuttle PharmaceuticalsSHPH$24.3M

What if Transcode Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,667,787

Per share 1,111,858× higher

Bitcoin $1.53T

$90,241.07

Per share 60,161× higher

Apple $5.02T

$296,253.02

Per share 197,502× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Transcode Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.